AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie (ABBV) is one of the stocks most watched ... And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward.

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

AbbVie (NYSE:ABBV) will report Q4 2024 results ... being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those ...

Investors who were hoping for huge dividend increases may want to adjust their expectations. Today, AbbVie's dividend payout ratio is 61% of 2024 earnings. That leaves plenty of room for future ...

Well before the market open, news broke of those two AbbVie price target increases ... Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever 3 High ...